期刊
EXPERT REVIEW OF VACCINES
卷 12, 期 6, 页码 617-629出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.13.40
关键词
carcinoembryonic antigen; clinical trials; immunotherapy; preclinical studies; vaccine
类别
资金
- NIH
- Center for Cancer Research, National Cancer Institute, NIH
Concurrent with the US FDA's approval of the first therapeutic cancer vaccine, and supported by mounting clinical evidence indicating that targeting carcinoembryonic antigen (CEA) can safely overcome pre-existing tolerance, a multitude of novel CEA cancer vaccines are now in various stages of development. Since cancer-driven immune suppression often limits the efficacy of vaccines, numerous strategies are being examined in both preclinical and clinical settings to overcome immunosuppressive elements, including the combined use of vaccines with certain chemotherapies, immune checkpoint inhibitors, small-molecule targeted therapies and radiation. This review discusses the current state and future direction of therapeutic cancer vaccines targeting CEA, based on advances achieved over the last 5 years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据